R. Khosravan

发表

Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics

C. Wetmore, Yanke Yu, S. DuBois, 2020, The AAPS Journal.

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors

K. Janeway, E. Wang, S. DuBois, 2021, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

R. Motzer, B. Rini, R. Khosravan, 2016, Clinical Pharmacokinetics.

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

G. Demetri, H. Guchelaar, H. Gelderblom, 2014, BMC Cancer.

Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

G. Haas, R. Khosravan, Pooja Manchandani, 2022, Clinical and translational science.

Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment

R. Khosravan, D. Mulford, L. Vernillet, 2005, American journal of therapeutics.

A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.

R. Motzer, Xin Huang, R. Khosravan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

R. Khosravan, L. Vernillet, B. Grabowski, 2006, Clinical pharmacokinetics.

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

S. Swan, T. Marbury, M. Toh, 2010, Journal of clinical pharmacology.

Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies.

Jean W. Lee, J. Fiene, R. Khosravan, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetic Interactions of Concomitant Administration of Febuxostat and NSAIDs

R. Khosravan, L. Vernillet, Jing-tao Wu, 2006, Journal of clinical pharmacology.

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

R. Khosravan, L. Vernillet, B. Grabowski, 2008, British journal of clinical pharmacology.

Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer.

M. Khan, R. Khosravan, A. Shojaei, 1999, International journal of pharmaceutics.

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

R. Khosravan, L. Vernillet, C. Lademacher, 2010, British journal of clinical pharmacology.

Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2004, Nucleosides, nucleotides & nucleic acids.

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

R. Khosravan, L. Vernillet, M. D. Mayer, 2006, Journal of clinical pharmacology.

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial

K. Janeway, A. Verschuur, L. Mascarenhas, 2019, Cancer Chemotherapy and Pharmacology.

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

Y. Bang, Keun-Wook Lee, D. Oh, 2013, Investigational New Drugs.

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

R. Salazar, J. Bellmunt, C. Montagut, 2013, Investigational New Drugs.

Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects

R. Khosravan, D. Mulford, L. Vernillet, 2011, Journal of clinical pharmacology.

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects

R. Khosravan, D. Mulford, L. Vernillet, 2005 .

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

E. Chan, D. Camidge, S. Leong, 2012, Cancer Chemotherapy and Pharmacology.

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2005 .

The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

R. Khosravan, M. Kukulka, L. Vernillet, 2008, Journal of clinical pharmacology.

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer

Weiwei Tan, K. Wilner, A. Bello, 2016, Clinical Cancer Research.

Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics

C. Wetmore, Yanke Yu, S. DuBois, 2020, The AAPS Journal.

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

A. Goldhirsch, G. Curigliano, M. Collier, 2013, Breast.

Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis

M. Toh, G. Ni, R. Khosravan, 2008 .

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

E. Raymond, J. Šufliarský, P. Ruff, 2018, Neuroendocrinology.

Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

P. Macdonald, B. Hunt, M. Becker, 2004 .

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors

C. Wetmore, E. Wang, S. DuBois, 2020, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors

C. Wetmore, A. Verschuur, E. Wang, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

A. Goldhirsch, G. Curigliano, M. Collier, 2013, Breast.

A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.

R. Motzer, Xin Huang, R. Khosravan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.